SeaTown Holdings Pte. Ltd. Sells 3,000 Shares of Eli Lilly and Company $LLY

Key Points

• SeaTown Holdings cut its Eli Lilly stake by 23.6% in Q4, selling 3,000 shares and retaining 9,725 shares worth about $10,451,000, which is roughly 6.1% of SeaTown’s holdings and its sixth-largest position.
• Eli Lilly just received FDA approval for oral weight‑loss drug Foundayo with production ready to scale, offering near-term revenue upside, but faces margin and market‑share pressure from Novo Nordisk’s lower‑priced Wegovy HD.
• The company reported an earnings beat (EPS $7.54 vs. $7.48) and revenue of $19.29B (up 42.6% YoY), and analysts remain broadly positive with a consensus “Moderate Buy” and a ~$1,222 price target after several upgrades.

SeaTown Holdings Pte. Ltd. decreased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 23.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,725 shares of the company's stock after selling 3,000 shares during the period. Eli Lilly and Company accounts for approximately 6.1% of SeaTown Holdings Pte. Ltd.'s holdings, making the stock its 6th biggest holding. SeaTown Holdings Pte. Ltd.'s holdings in Eli Lilly and Company were worth $10,451,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Exencial Wealth Advisors LLC raised its holdings in Eli Lilly and Company by 189.6% during the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company's stock worth $13,283,000 after purchasing an additional 11,396 shares during the last quarter. Rede Wealth LLC bought a new stake in Eli Lilly and Company during the 3rd quarter worth about $487,000. Central Pacific Bank Trust Division raised its holdings in Eli Lilly and Company by 25.8% during the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company's stock worth $6,859,000 after purchasing an additional 1,843 shares during the last quarter. Cidel Asset Management Inc. raised its holdings in Eli Lilly and Company by 26.5% during the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock worth $20,392,000 after purchasing an additional 5,591 shares during the last quarter. Finally, Spire Wealth Management raised its holdings in Eli Lilly and Company by 2.2% during the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company's stock worth $29,789,000 after purchasing an additional 592 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval and commercial setup: Lilly secured approval for its oral weight‑loss drug Foundayo and management says production is ready to scale, supporting near‑term revenue upside from obesity treatments. Great News for Eli Lilly Stock Investors!
• Positive Sentiment: Buy arguments and analyst support: multiple bullish writeups (including a "3 Reasons To Buy" piece and a modest price‑target raise after approval) highlight durable cash flows from GLP‑1 drugs and refreshed upside assumptions. 3 Reasons To Buy Eli Lilly Now Price Target Raised After FDA Approval
• Positive Sentiment: Pipeline diversification: Lilly amended its collaboration with AC Immune to advance next‑generation tau inhibitors toward IND‑enabling studies in 2026, expanding long‑term Alzheimer’s/neurodegeneration exposure beyond metabolic drugs. Eli Lilly Extends AC Immune Tau Pact
• Neutral Sentiment: Investor attention and commentary: Zacks and other outlets note heavy investor interest and that Lilly has lagged recent market gains despite its headline activity — useful context for short‑term volume/volatility. Eli Lilly (LLY) Ascends But Remains Behind Market
• Negative Sentiment: Competitive pricing pressure: Novo Nordisk launched a higher‑dose Wegovy at a significantly lower cash price than Lilly’s Zepbound/Foundayo positioning, creating margin and market‑share risks in the obesity market. Novo Nordisk Unveils $399 Wegovy HD
• Negative Sentiment: Analyst downgrade / short‑term sell pressure: reports show at least one analyst downgrade that pushed intraday selling and headlines about the stock dipping after the new approval, reflecting investor sensitivity to competition and side‑effect narratives. Trading Down on Analyst Downgrade Stock Dips Following FDA Approval
• Negative Sentiment: Valuation/forecast adjustments: at least one research note trimmed fair‑value assumptions slightly while leaving a high base case, underscoring debates over how much obesity/diabetes upside is already priced in. Obesity & Diabetes Story Reframes Investment Narrative

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $952.24 on Thursday. The company has a market capitalization of $899.69 billion, a price-to-earnings ratio of 41.49, a P/E/G ratio of 1.09 and a beta of 0.51. The firm's 50 day simple moving average is $987.31 and its 200 day simple moving average is $973.10. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts' consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. Eli Lilly and Company's revenue for the quarter was up 42.6% on a year-over-year basis. During the same period last year, the company posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on LLY. Royal Bank Of Canada began coverage on Eli Lilly and Company in a report on Tuesday, February 24th. They set an "outperform" rating and a $1,250.00 price objective for the company. Leerink Partners boosted their price objective on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the stock an "outperform" rating in a report on Thursday, February 5th. Barclays began coverage on Eli Lilly and Company in a report on Thursday, February 19th. They set an "overweight" rating and a $1,350.00 price objective for the company. Jefferies Financial Group set a $1,300.00 price objective on Eli Lilly and Company and gave the stock a "buy" rating in a report on Friday, March 13th. Finally, Daiwa Securities Group boosted their price objective on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a "buy" rating in a report on Wednesday, February 18th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $1,222.22.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.